Huang, Jason M.
Khurana, Rahul N.
Ghanekar, Avanti
Wang, Pin-wen
Day, Bann-Mo
Blodi, Barbara A.
Domalpally, Amitha
Quezada-Ruiz, Carlos
Ip, Michael S.
Funding for this research was provided by:
Genentech
Research to Prevent Blindness
Article History
Received: 9 December 2020
Revised: 19 March 2021
Accepted: 27 April 2021
First Online: 6 October 2021
Declarations
:
: Dr. Ip served as a consultant for Genentech, Allergan, Clearside, Novartis, Allegro, Alimera, and Regenxbio, outside the submitted work. Dr. Khurana reports grants from and served as a consultant for Allergan and Apellis; reports grants from Chengdu Kanghong and Roche; and served as a consultant for Merck, Genentech, Alkahest, Regeneron, and Clearside Biomedical, outside the submitted work. Dr. Ghanekar reports personal fees from and served as a consultant for Genentech Inc. during conduct of the study. Dr. Wang reports personal fees from Genentech Inc., Philips Healthcare, and Adverum Biotechnologies, outside the submitted work.